The Nociceptin/Orphanin FQ Receptor Antagonist UFP-101 Reduces Microvascular Inflammation to Lipopolysaccharide In Vivo

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Brookes, Zoë L S ^a   Stedman, Emily N ^a   Brown, Nicola J ^a   Hebbes, Christopher P ^b   Guerrini, Remo ^c   Calo, Girolamo ^c   Reilly, Charles S ^a   Lambert, David G ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; UFP 101; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ROLLING; MALE; MESENTERIC ARTERY; MESENTERY BLOOD FLOW; MICROVASCULAR INFLAMMATION; NONHUMAN; RAT; SEPSIS; VASCULAR ENDOTHELIUM; VASCULITIS;

ANIMALS; CARDIOVASCULAR SYSTEM; CHO CELLS; CRICETINAE; CRICETULUS; FLUORESCEIN-5-ISOTHIOCYANATE; INFLAMMATION; LEUKOCYTE ROLLING; MALE; MICROCIRCULATION; MICROVESSELS; OPIOID PEPTIDES; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECOMBINANT PROTEINS;

EID: 84884518274     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074943     Document Type: Article

References (37)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2: 1303-1310. PubMed: 11445675.
2. Lambert DG, (2008) The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 7: 694-710. doi:10.1038/nrd2572. PubMed: 18670432.
3. Granata F, Potenza RL, Fiori A, Strom R, Caronti B, et al. (2003) Expression of OP4 (ORL1, NOP1) receptors in vascular endothelium. Eur J Pharmacol 482: 17-23. doi:10.1016/j.ejphar.2003.09.049. PubMed: 14660000.
4. Madeddu P, Salis MB, Milia AF, Emanueli C, Guerrini R, et al. (1999) Cardiovascular effects of nociceptin in unanesthetized mice. Hypertension 33: 914-919. doi:10.1161/01.HYP.33.3.914. PubMed: 10082508.
5. Hashiba E, Hirota K, Kudo T, Calo' G, Guerrini R, et al. (2003) Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 367: 342-347. doi:10.1007/s00210-003-0704-9. PubMed: 12690425.
6. Kapusta DR, Kenigs VA, (1999) Cardiovascular and renal responses produced by central orphanin FQ/nociceptin occur independent of renal nerves. Am J Physiol 277: R987-R995. PubMed: 10516236.
7. Champion HC, Pierce RL, Kadowitz PJ, (1998) Nociceptin, a novel endogenous ligand for the ORL1 receptor, dilates isolated resistance arteries from the rat. Regul Pept 78: 69-74. doi:10.1016/S0167-0115(98)00117-7. PubMed: 9879748.
8. Burmeister MA, Ansonoff MA, Pintar JE, Kapusta DR, (2008) Nociceptin/orphanin FQ (N/OFQ)-evoked bradycardia, hypotension, and diuresis are absent in N/OFQ peptide (NOP) receptor knockout mice. J Pharmacol Exp Ther 326: 897-904. doi:10.1124/jpet.107.135905. PubMed: 18539652.
9. Brookes ZL, Stedman EN, Guerrini R, Lawton BK, Calo G, et al. (2007) Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. Am J Physiol Heart Circ Physiol 293: H2977-H2985. doi:10.1152/ajpheart.00448.2007. PubMed: 17766480.
10. Williams JP, Thompson JP, Rowbotham DJ, Lambert DG, (2008) Human peripheral blood mononuclear cells produce pre-pro-nociceptin/orphanin FQ mRNA. Anesth Analg 106: 865-866. doi:10.1213/ane.0b013e3181617646. PubMed: 18292431.
11. Williams JP, Thompson JP, McDonald J, Barnes TA, Cote T, et al. (2007) Human peripheral blood mononuclear cells express nociceptin/orphanin FQ, but not mu, delta, or kappa opioid receptors. Anesth Analg 105: 998-1005. doi:10.1213/01.ane.0000278865.11991.9d. PubMed: 17898379.
12. Serrano-Gomez A, Thompson JP, Lambert DG, (2011) Nociceptin/orphanin FQ in inflammation and sepsis. Br J Anaesth 106: 6-12. doi:10.1093/bja/aeq337. PubMed: 21138900.
13. Acosta C, Davies A, (2008) Bacterial lipopolysaccharide regulates nociceptin expression in sensory neurons. J Neurosci Res 86: 1077-1086. doi:10.1002/jnr.21565. PubMed: 18027846.
14. Leggett JD, Dawe KL, Jessop DS, Fulford AJ, (2009) Endogenous nociceptin/ orphanin FQ system involvement in hypothalamic-pituitary-adrenal axis responses: relevance to models of inflammation. J Neuroendocrinol 21: 888-897. doi:10.1111/j.1365-2826.2009.01912.x. PubMed: 19732291.
15. Acosta C, Davies A, (2008) Bacterial lipopolysaccharide regulates nociceptin expression in sensory neurons. J Neurosci Res 86: 1077-1086. doi:10.1002/jnr.21565. PubMed: 18027846.
16. Miller TR, Fulford AJ, (2007) Regulation of nociceptin/orpahnin FQ secretion by immune cells and functional modulation of interleukin-2. Peptides 28: 2243-2252. doi:10.1016/j.peptides.2007.09.004. PubMed: 17950489.
17. Carvalho D, Petronilho F, Vuolo F, Machado RA, Constantino L, et al. (2008) The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. Intensive Care Med 34: 2284-2290. doi:10.1007/s00134-008-1313-3. PubMed: 18846364.
18. Gardiner SM, Kemp PA, March JE, Bennett T, (1995) Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats. Br J Pharmacol 116: 2005-2016. doi:10.1111/j.1476-5381.1995.tb16405.x. PubMed: 8640339.
19. McGown CC, Brown NJ, Hellewell PG, Reilly CS, Brookes ZL, (2010) Beneficial microvascular and anti-inflammatory effects of pravastatin during sepsis involve nitric oxide synthase III. Br J Anaesth 104: 183-190. doi:10.1093/bja/aep361. PubMed: 20086063.
20. Calo G, Guerrini R, Rizzi A, Salvadori S, Burmeister M, et al. (2005) UFP-101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ Receptor: CNS. Drug Res 11: 97-112.
21. Brookes ZL, Kaufman S, (2003) Myogenic responses and compliance of mesenteric and splenic vasculature in the rat. Am J Physiol Regul Integr Comp Physiol 284: R1604-R1610. PubMed: 12609815.
22. Brookes ZL, Kaufman S, (2005) Effects of atrial natriuretic peptide on the extrasplenic microvasculature and lymphatics in the rat in vivo. J Physiol 565: 269-277. doi:10.1113/jphysiol.2005.083147. PubMed: 15718260.
23. Guerrini R, Calo G, Rizzi A, Bianchi C, Lazarus LH, et al. (1997) Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem 40: 1789-1793. doi:10.1021/jm970011b. PubMed: 9191955.
24. Calo G, Rizzi A, Rizzi D, Bigoni R, Guerrini R, et al. (2002) [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 136: 303-311. doi:10.1038/sj.bjp.0704706. PubMed: 12010780.
25. Bycroft BW, Weng C, Chan WC, Chhabra SR, Hone ND, (1993) A novel lysine-protecting procedure for continuous flow solid phase synthesis of branched peptides. J Chem Soc Chem Commun 9: 778.
26. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108. doi:10.1016/0006-2952(73)90196-2. PubMed: 4202581.
27. Kitayama M, Barnes TA, Carra G, McDonald J, Calo G, et al. (2003) Pharmacological Profile of the Cyclic Nociceptin/Orphanin FQ Analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe 1,Cys10,14]N/OFQ(1-14)NH2. Naunyn-Schmiedebergs Arch Pharmacol 368: 528-537.
28. Reed MW, Miller FN, Wieman TJ, Tseng MT, Pietsch CG, (1988) The effect of photodynamic therapy on the microcirculation. J Surg Res 45: 452-459. doi:10.1016/0022-4804(88)90195-3. PubMed: 2972887.
29. McDonald J, Barnes TA, Okawa H, Williams J, et al,. (2003) Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system. Br J Pharmacol 140: 61-70. doi:10.1038/sj.bjp.0705401. PubMed: 12967935.
30. Brookes ZL, Mansart A, McGown CC, Ross JJ, Reilly CS, et al. (2009) Macromolecular leak from extrasplenic lymphatics during endotoxemia. Lymph Res Biol 7: 131-137. doi:10.1089/lrb.2008.1019. PubMed: 19778200.
31. Williams JP, Thompson JP, Young SP, Gold SJ, McDonald J, et al. (2010) Nociceptin and urotensin-II concentrations in critically ill patients with sepsis. Br J Anaesth 100: 810-814. PubMed: 18430746.
32. Ibba M, Kitayama M, McDonald J, Calo G, Guerrini R, et al. (2008) Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors. Naunyn Schmiedebergs Arch Pharmacol378: 553-561. doi:10.1007/s00210-008-0350-3. PubMed: 18807245.
33. Hashiba E, Lambert DG, Farkas J, Toth G, Smith G, (2002) Comparison of the binding of [3H]nociceptin/orphaninFQ(1-13)NH(2), [3H]nociceptin/orphaninFQ(1-17)OH and [125I]Tyr(14)nociceptin/orphaninFQ(1-17)OH to recombinant human and native rat cerebrocortical nociceptin/orphanin FQ receptors. Neurosci Lett 328: 5-8. doi:10.1016/S0304-3940(02)00259-8. PubMed: 12123846.
34. Niwa H, Rowbotham DJ, Lambert DG, (2012) Evaluation of primary opioid receptor antibodies for use in western blotting. Br J Anaesth 108: 530-532. doi:10.1093/bja/aes015. PubMed: 22337965.
35. Hébert MT, Marshall JM, (1988) Direct observations of effects of baroreceptor stimulation on mesenteric circulation of the rat. J Physiol 400: 29-44. PubMed: 3418527.
36. Burmeister MA, Kapusta DR, (2007) Centrally administered nociceptin/orphanin FQ (N/OFQ) evokes bradycardia, hypotension, and diuresis in mice via activation of central N/OFQ peptide receptors. J Pharmacol Exp Ther 322: 324-331. doi:10.1124/jpet.107.120394. PubMed: 17452419.
37. Krowicki ZK, Kapusta DR, (2006) Tonic nociceptinergic inputs to neurons in the hypothalamic paraventricular nucleus contribute to sympathetic vasomotor tone and water and electrolyte homeostasis in conscious rats. J Pharmacol Exp Ther 317: 446-453. PubMed: 16407463.